Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Wilms Tumor 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Prostatic Diseases 1Primary Myelofibrosis 1Premenopausal HR+/HER2- Metastatic Breast Cancer 1Polycythemia Vera 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Myeloproliferative Disorders 1

Interventions

Bevacizumab 76Fluorouracil 56Cetuximab 47Leucovorin 44Oxaliplatin 43pembrolizumab 35Irinotecan 34Folfox protocol 24Capecitabine 24HMPL-013 22Specimen Handling 18trifluridine tipiracil drug combination 16Nivolumab 15Blood Specimen Collection 15Panitumumab 14regorafenib 13Magnetic Resonance Spectroscopy 13Trifluridine 12Standard of Care 12Gemcitabine 12Biopsy 12Cisplatin 11sintilimab 10Interviews as Topic 10IFL protocol 10Drug Therapy 10Carboplatin 9tislelizumab 8Trastuzumab 8Cyclophosphamide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Colorectal Neoplasms × talazoparib × Clear all
NCT04511039 2026-05-04

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Roswell Park Cancer Institute

Phase 1 Recruiting
45 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡